News | 25 February 2023
EMA recommends refusal of the marketing authorization for Lagevrio
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
Ghostine has served as CEO of Geneva-based Firmenich, the world's largest privately owned perfume and taste company, since 2014.
The company has reported total income of Rs. 691.9 crores during the quarter ended December 31, 2022
Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
Ayurveda is one of the most advanced sciences of its times
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
A total of 889 M&A deals were announced in the medical devices sector in 2022 worth $93 billion
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
The new sterile filling line meets cGMP aseptic filling regulatory requirements
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
There is a fast resurgence in the transplant activities post COVID
Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
The partnership is announced at Aero India 2023, Bangalore
.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
Subscribe To Our Newsletter & Stay Updated
